Beam Therapeutics Inc.

19.54
-0.63 (-3.12%)
At close: Apr 25, 2025, 3:59 PM
20.40
4.40%
After-hours: Apr 25, 2025, 05:53 PM EDT

Beam Therapeutics Statistics

Share Statistics

Beam Therapeutics has 99.84M shares outstanding. The number of shares has increased by 21.3% in one year.

Shares Outstanding 99.84M
Shares Change (YoY) 21.3%
Shares Change (QoQ) 20.57%
Owned by Institutions (%) 98.87%
Shares Floating 85.36M
Failed to Deliver (FTD) Shares 61
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 14.74M, so 14.76% of the outstanding shares have been sold short.

Short Interest 14.74M
Short % of Shares Out 14.76%
Short % of Float 18.34%
Short Ratio (days to cover) 6.68

Valuation Ratios

The PE ratio is -5.42 and the forward PE ratio is -4.11. Beam Therapeutics's PEG ratio is -0.03.

PE Ratio -5.42
Forward PE -4.11
PS Ratio 32.14
Forward PS 3.7
PB Ratio 2.78
P/FCF Ratio -5.73
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Beam Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.22.

Current Ratio 4.82
Quick Ratio 4.82
Debt / Equity 0.22
Debt / EBITDA -0.39
Debt / FCF -0.45
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $131.51K
Profits Per Employee $-780K
Employee Count 483
Asset Turnover 0.06
Inventory Turnover n/a

Taxes

Income Tax 39K
Effective Tax Rate -0.01%

Stock Price Statistics

The stock price has increased by -6.67% in the last 52 weeks. The beta is 2.02, so Beam Therapeutics's price volatility has been higher than the market average.

Beta 2.02
52-Week Price Change -6.67%
50-Day Moving Average 23.29
200-Day Moving Average 25.16
Relative Strength Index (RSI) 52.87
Average Volume (20 Days) 2.18M

Income Statement

In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.

Revenue 63.52M
Gross Profit 63.52M
Operating Income -415.57M
Net Income -376.74M
EBITDA -415.57M
EBIT -415.57M
Earnings Per Share (EPS) -4.58
Full Income Statement

Balance Sheet

The company has 281.97M in cash and 161.43M in debt, giving a net cash position of 120.54M.

Cash & Cash Equivalents 281.97M
Total Debt 161.43M
Net Cash 120.54M
Retained Earnings -1.57B
Total Assets 1.1B
Working Capital 696.08M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -347.25M and capital expenditures -8.95M, giving a free cash flow of -356.19M.

Operating Cash Flow -347.25M
Capital Expenditures -8.95M
Free Cash Flow -356.19M
FCF Per Share -4.33
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -654.25% and -593.13%.

Gross Margin 100%
Operating Margin -654.25%
Pretax Margin -593.06%
Profit Margin -593.13%
EBITDA Margin -654.25%
EBIT Margin -654.25%
FCF Margin -560.77%

Dividends & Yields

BEAM pays an annual dividend of $1.12, which amounts to a dividend yield of 4.8%.

Dividend Per Share $1.12
Dividend Yield 4.8%
Dividend Growth (YoY) 0%
Payout Ratio -24.56%
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BEAM is $41, which is 103.4% higher than the current price. The consensus rating is "Buy".

Price Target $41
Price Target Difference 103.4%
Analyst Consensus Buy
Analyst Count 11
Stock Forecasts

Scores

Altman Z-Score 0.68
Piotroski F-Score 2